Skip to main content
SpringerLink
Log in
Book cover

Developments in T Cell Based Cancer Immunotherapies

  • Book
  • © 2015

Overview

Editors:
  1. Paolo A. Ascierto

    1. Unit of Melanoma & Cancer Immunotherapy, National Tumor Institute Fondazione G., Naples, Italy

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. David F. Stroncek

    1. Department of Transfusion Medicine, National Institutes of Health, Bethesda, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Ena Wang

    1. Department of Transfusion Medicine, National Institutes of Health, BETHESDA, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Summarizes and discusses current advancements in T cell-based anticancer immunotherapy
  • Comprehensively covers T cell biology, including T cell lineage differentiation stages, mechanisms of anergy and activation, exhaustion, senescence, stemness, and strategies of deregulation for therapeutic development
  • Explores novel approach of hematopoietic stem cell transplantation as a method of immune therapy for cancer

Part of the book series: Cancer Drug Discovery and Development (CDD&D)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (14 chapters)

  1. Front Matter

    Pages i-xv
    Download chapter PDF

  2. Insights on Peptide Vaccines in Cancer Immunotherapy

    • Kwong Y. Tsang, Caroline Jochems, Jeffrey Schlom
    Pages 1-27

  3. Strategies for Improving Vaccines to Elicit T Cells to Treat Cancer

    • Jay A. Berzofsky, Lauren V. Wood, Masaki Terabe
    Pages 29-52

  4. T Cell Fate in the Tumor Microenvironment

    • Joel Crespo, Ilona Kryczek, Theodore Welling, Shuang Wei, Weiping Zou
    Pages 53-74

  5. Influence of Antigen Receptor Avidity, Affinity, and Specificity on Genetically Engineered T Cells

    • Kaoru Nagato, Timothy T. Spear, Michael I. Nishimura
    Pages 75-98

  6. Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy

    • Davide Bedognetti, Sara Tomei, Wouter Hendrickx, Francesco M. Marincola, Ena Wang
    Pages 99-127

  7. Production of Clinical T Cell Therapies

    • David Stroncek, Jianjian Jin, Virginia David-Ocampo, Vicki Fellowes, Larry Moses, Marianna Sabatino
    Pages 129-150

  8. Clinical Success of Adoptive Cell Transfer Therapy Using Tumor Infiltrating Lymphocytes

    • Jessica Chacon, Krit Ritthipichai, Geok Sim, Michiko Harao, Jie Qing Chen, Caitlin Creasy et al.
    Pages 151-181

  9. Harnessing Stem Cell-Like Memory T Cells for Adoptive Cell Transfer Therapy of Cancer

    • Enrico Lugli, Luca Gattinoni
    Pages 183-209

  10. T Cell Blockade Immunotherapy Against Cancer and Abscopal Effect in Combination Therapy

    • Giuseppe V. Masucci, Luigi De Petris, Andreas Lundqvist, Rolf Kiessling, Rolf Lewensohn
    Pages 211-229

  11. T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer

    • Patrick A. Ott, F. Stephen Hodi
    Pages 231-244

  12. Enhancing T Cell Performance Against Cancer in Combination Treatment Strategies

    • Maria Libera Ascierto, Salvador Martin Algarra, Ignacio Melero, Paolo A. Ascierto
    Pages 245-258

  13. Chimeric Antigen Receptor (CAR) T Cells

    • Daniel W. Lee, Alan S. Wayne
    Pages 259-280

  14. Rapamycin-Resistant T Cells and Pentostatin-Based Immuno-Selective Conditioning for the Allogeneic T Cell Therapy of Cancer

    • Daniel H. Fowler, David C. Halverson
    Pages 281-302

  15. Erratum

    • Paolo A. Ascierto, David F. Stroncek, Ena Wang
    Pages E1-E1

  16. Back Matter

    Pages 303-305
    Download chapter PDF
Back to top

Keywords

About this book

This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed.

Editors and Affiliations

  • Unit of Melanoma & Cancer Immunotherapy, National Tumor Institute Fondazione G., Naples, Italy

    Paolo A. Ascierto

  • Department of Transfusion Medicine, National Institutes of Health, Bethesda, USA

    David F. Stroncek

  • Department of Transfusion Medicine, National Institutes of Health, BETHESDA, USA

    Ena Wang

About the editors

Ena Wang, MD, is Director of Molecular Science, Infectious Diseases and Immunogenetics Section at the National Institutes of Health. The focus of her research is the identification of genetic traits in humans that could explain the relationship between pathogens and the host with particular interest in cancer and chronic infections During her career at NIH, Dr. Wang was twice granted the Investigator Travel Fellowship Award; received an NIH Bench-to-Bedside Award in 2002; received the Minority Award as a mentor and principle investigator in 2002; received the NCI Director’s 2006 Intramural Innovation Award as co-investigator in 2006; and received the Clinic Center Director’s Award for scientific excellence in 2007. Dr. Wang has authored 17 book chapters and published more than 130 peer reviewed articles. Her scientific papers have received more than 6,500 citations.

Paolo Antonio Ascierto, MD, is Vice Director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Institute Fondazione G. Pascale in Naples, Italy. Dr. Ascierto has published more than 117 scientific papers, which have received more than 2,100 citations.

David F. Stroncek, MD, is the Chief of the Cell Processing Section at the Department of Transfusion Medicine at the National Institutes of Health. Dr. Stroncek has published more than 264 scientific papers, which have received more than 5,300 citations.

Bibliographic Information

  • Book Title: Developments in T Cell Based Cancer Immunotherapies

  • Editors: Paolo A. Ascierto, David F. Stroncek, Ena Wang

  • Series Title: Cancer Drug Discovery and Development

  • DOI: https://doi.org/10.1007/978-3-319-21167-1

  • Publisher: Humana Cham

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Springer International Publishing Switzerland 2015

  • Hardcover ISBN: 978-3-319-21166-4Published: 04 December 2015

  • Softcover ISBN: 978-3-319-79330-6Published: 14 March 2019

  • eBook ISBN: 978-3-319-21167-1Published: 26 November 2015

  • Series ISSN: 2196-9906

  • Series E-ISSN: 2196-9914

  • Edition Number: 1

  • Number of Pages: XV, 305

  • Number of Illustrations: 26 illustrations in colour

  • Topics: Cancer Research, Immunology, Molecular Medicine, Cell Biology

Publish with us

Policies and ethics

Back to top

Search

Navigation